 SAN JOSE, Calif., March 09, 2021 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has developed and completed evaluations at the end of February 2021 for a new generation multi-cancer detection sensor named CDA Pro Sensor CDAPS. CDAPS is a technology breakthrough with improved performance over the previous generation cancer detection sensor in a number of areas, including detection signal stability, sensor device yield, sensor cost, and detection sensitivity and specificity. In particular, sensor cost has been reduced by 137 and both cancer detection sensitivity and specificity reached over 95 in a retrospective clinical sample test. The new generation sensor i.e. CDAPS is capable of measuring subtle changes in bio-physical properties in a blood sample, with improvements in its design, fabrication and packaging processes, and it is expected that CDAPS will enhance the competitiveness of the Company in cancer screening. 